exactly, focus on approval to start the liftoff, Everything else is noise. Forget moonshot mention, forget whistleblower , forget apes, forget 3 million loan and buyout, forget may flowers. Keytruda patent expires in 5 years and then NWBO will be raking in merck type profits. I doubt they even PR submittal approval since it would give shorts a timeline to coordinate an attack. ASCO is nothing burger since the same attendees who allready know treatment works will be there. I just wonder if merck will continue to put the kibosh on mention of dc-vax combo trial. Predictions lead to disappointment. Now enjoy the day and coming weekend.